Anesthesia and Analgesia in Laboratory Animals
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Table 2. 2012 AGS Beers Criteria for Potentially
Table 2. 2012 AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults Strength of Organ System/ Recommendat Quality of Recomm Therapeutic Category/Drug(s) Rationale ion Evidence endation References Anticholinergics (excludes TCAs) First-generation antihistamines Highly anticholinergic; Avoid Hydroxyzin Strong Agostini 2001 (as single agent or as part of clearance reduced with e and Boustani 2007 combination products) advanced age, and promethazi Guaiana 2010 Brompheniramine tolerance develops ne: high; Han 2001 Carbinoxamine when used as hypnotic; All others: Rudolph 2008 Chlorpheniramine increased risk of moderate Clemastine confusion, dry mouth, Cyproheptadine constipation, and other Dexbrompheniramine anticholinergic Dexchlorpheniramine effects/toxicity. Diphenhydramine (oral) Doxylamine Use of diphenhydramine in Hydroxyzine special situations such Promethazine as acute treatment of Triprolidine severe allergic reaction may be appropriate. Antiparkinson agents Not recommended for Avoid Moderate Strong Rudolph 2008 Benztropine (oral) prevention of Trihexyphenidyl extrapyramidal symptoms with antipsychotics; more effective agents available for treatment of Parkinson disease. Antispasmodics Highly anticholinergic, Avoid Moderate Strong Lechevallier- Belladonna alkaloids uncertain except in Michel 2005 Clidinium-chlordiazepoxide effectiveness. short-term Rudolph 2008 Dicyclomine palliative Hyoscyamine care to Propantheline decrease Scopolamine oral secretions. Antithrombotics Dipyridamole, oral short-acting* May -
Use of Tribromoethanol (Avertin)”
Washington State University Institutional Animal Care and Use Committee Policy #32 “Use of Tribromoethanol (Avertin)” Approval Date: 11/18/2019 (Replacing Version: 11/16/2016) A. Purpose To provide guidance on the use of tribromoethanol (TBE) in animal studies and to provide standardized methods for its preparation and storage. B. Background In compliance with federal Animal Welfare Regulations and guidance from regulatory and oversight bodies, the IACUC expects that investigators use pharmaceutical grade medications whenever they are available, even in acute-terminal procedures.1,2 Non- pharmaceutical grade compounds should only be used after specific review and approval by the IACUC for reasons such as scientific necessity, or non-availability of an acceptable veterinary or human pharmaceutical-grade product. Cost savings is not adequate justification for using non-pharmaceutical grade compounds in research animals (see WSU IACUC Policy #29, Use of Non-Pharmaceutical Grade Substances in Laboratory Animals). Tribromoethanol (TBE) is an injectable anesthetic previously manufactured under the trade name Avertin®; however, this product is no longer available in pharmaceutical grade. In addition, TBE can cause a number of deleterious effects when administered to animals2-8: • TBE degrades in the presence of heat or light to produce the toxic byproducts, dibromoacetaldehyde and hydrobromic acid, which are nephrotoxic and hepatotoxic. • Administration of degraded TBE solutions has been associated with post- anesthetic illness and death, often within 24 hours of injection. 1 • Peritonitis abdominal adhesions and ileus (reduced gut motility) leading to death of the animal can occur following intraperitoneal (IP) administration of TBE. • Other side effects include muscle necrosis, hepatic damage, bacterial translocation, sepsis, and serositis of abdominal organs. -
Guidelines for Use of Tribromoethanol in Rodents
Guidelines for Use of Tribromoethanol in Rodents The expectation is that IACUC Guidelines will be followed as best practice. They allow the Animal Care & Use Program to attain acceptable performance outcomes to meet the intent of the regulations. As such, any planned variation from the guidelines requires prior IACUC approval and must be based on a scientific rationale. Introduction Tribromoethanol (TBE) is a popular injectable anesthetic agent used in rodents. It was once manufactured specifically for use as an anesthetic by Winthrop Laboratories under the trade name Avertin®, but this product is no longer available. Currently, it is only available as a non-pharmaceutical- grade powder that must be aseptically reconstituted for injection. When used properly, it has a good margin of safety and it is still popular for certain research applications. TBE is considered a non-pharmaceutical grade drug and as such its use must be in accord with these guidelines and the UGA IACUC Policy on the Use of Outdated Drugs and Materials, Non-pharmaceutical Grade Drugs, and Controlled Substances. The PI is also required to provide information regarding scientific necessity and must take into account the following when proposing the use of this agent in rodents: According to a recent review (Lab Animal 34(10):47-52) tribromoethanol has been associated with serious post-anesthetic effects and inconsistent and variable anesthetic effects. Have these effects been observed by your laboratory? Have alternative anesthetics for this procedure been considered? If so, why has TBE been chosen over these alternatives? Contact your attending veterinarian for consultation on the use of anesthetics. -
Appendix A: Potentially Inappropriate Prescriptions (Pips) for Older People (Modified from ‘STOPP/START 2’ O’Mahony Et Al 2014)
Appendix A: Potentially Inappropriate Prescriptions (PIPs) for older people (modified from ‘STOPP/START 2’ O’Mahony et al 2014) Consider holding (or deprescribing - consult with patient): 1. Any drug prescribed without an evidence-based clinical indication 2. Any drug prescribed beyond the recommended duration, where well-defined 3. Any duplicate drug class (optimise monotherapy) Avoid hazardous combinations e.g.: 1. The Triple Whammy: NSAID + ACE/ARB + diuretic in all ≥ 65 year olds (NHS Scotland 2015) 2. Sick Day Rules drugs: Metformin or ACEi/ARB or a diuretic or NSAID in ≥ 65 year olds presenting with dehydration and/or acute kidney injury (AKI) (NHS Scotland 2015) 3. Anticholinergic Burden (ACB): Any additional medicine with anticholinergic properties when already on an Anticholinergic/antimuscarinic (listed overleaf) in > 65 year olds (risk of falls, increased anticholinergic toxicity: confusion, agitation, acute glaucoma, urinary retention, constipation). The following are known to contribute to the ACB: Amantadine Antidepressants, tricyclic: Amitriptyline, Clomipramine, Dosulepin, Doxepin, Imipramine, Nortriptyline, Trimipramine and SSRIs: Fluoxetine, Paroxetine Antihistamines, first generation (sedating): Clemastine, Chlorphenamine, Cyproheptadine, Diphenhydramine/-hydrinate, Hydroxyzine, Promethazine; also Cetirizine, Loratidine Antipsychotics: especially Clozapine, Fluphenazine, Haloperidol, Olanzepine, and phenothiazines e.g. Prochlorperazine, Trifluoperazine Baclofen Carbamazepine Disopyramide Loperamide Oxcarbazepine Pethidine -
Ketamine As a General Anesthesia Adjunct Michaela Wilcox, DNP
Ketamine as a General Anesthesia Adjunct Michaela Wilcox, DNP (c), RN Dept. of Nurse Anesthesia, Moffett & Sanders School of Nursing, Samford University Structured Abstract Background Ketamine is a unique anesthetic agent with both anesthetic and analgesic properties. Ketamine is primarily a N-Methyl-D-Aspartic acid (NMDA) antagonist that also works on glutamine, nicotinic, muscarinic, monoaminergic and opioid receptors. The uses of ketamine are numerous and include treatment of chronic pain, acute pain, depression, as a multimodal pain adjunct, opioid-sparing agent and as an adjunct in enhanced recovery after surgery (ERAS) protocols. A 49-year-old female presented for a lumbar lateral interbody fusion extreme, anterior lumbar spine arthrodesis L3/4 with revision and instrumentation. Based on the surgical need for both sensory and motor nerve monitoring intraoperatively, the anesthetic plan included minimal sevoflurane, succinylcholine for induction and a propofol intravenous (IV) infusion with boluses of ketamine to maintain unconsciousness. A bispectral index (BIS) monitor (Aspect Medical Systems, Natick, MA) was placed on the patient’s forehead prior to induction and utilized intraoperatively to maintain a goal of 40-60. General anesthesia was achieved with fentanyl 100 mcg, lidocaine 100 mg, propofol 200 mg, ketamine 50 mg and succinylcholine 160 mg IV. Laryngoscopy was successfully performed using a McGrath MAC video laryngoscope (Medtronic, Minneapolis, MN). Following induction, a propofol IV infusion was initiated and sevoflurane maintained at 0.3 minimum alveolar concentration. Ketamine 10 mg IV was administered every hour. Upon conclusion of the procedure, the patient was extubated and transported to postoperative recovery unit, where she had no complaints of nausea, vomiting or pain. -
(Antimuscarinic) Drugs?
© July - August 2018 How well do you know your anticholinergic (antimuscarinic) drugs? nticholinergic drugs, prescribed for a variety of clini- Acal conditions, are amongst the most frequently used prescription drugs in BC (Table 1). Also referred to as “an- timuscarinics,” such drugs specifically block muscarinic receptors for acetylcholine (ACh).1 Muscarinic ACh recep- tors are important in the parasympathetic nervous system that governs heart rate, exocrine glands, smooth muscles, clude drugs whose active metabolites are potent- as well as brain function. In contrast, nicotinic ACh recep- ly antimuscarinic,5 or which often cause typical tors stimulate contraction of striated muscles. This Letter is AC adverse effects such as dry mouth or urinary intended to remind clinicians of commonly used drugs that retention.6 People taking antihistamines, antide- have anticholinergic (AC), or technically, antimuscarinic pressants, antipsychotics, opioids, antimuscarinic properties, and of their potential adverse effects. inhalers, or many other drugs need to know that Beneficial and harmful effects of anticholinergic drugs have blockade of ACh receptors can cause bothersome been known for centuries. In Homer’s Odyssey, the nymph or even dangerous adverse effects (Table 3). pharmacologist Circe utilized central effects of atropinics Subtle and not-so-subtle toxicity in the common plant jimson weed (Datura stramonium) to cause delusions in the crew of Odysseus. Believing they Students often learn the adverse effects of anticho- had been turned into pigs, they could be herded.2 linergics from a mnemonic, e.g.: “Blind as a bat, Sometimes a drug is recommended specifically for its an- mad as a hatter, red as a beet, hot as a hare, dry as ticholinergic potency. -
Reference List of Drugs with Potential Anticholinergic Effects 1, 2, 3, 4, 5
ANTICHOLINERGICS: Reference List of Drugs with Potential Anticholinergic Effects 1, 2, 3, 4, 5 J Bareham BSP © www.RxFiles.ca Aug 2021 WHENEVER POSSIBLE, AVOID DRUGS WITH MODERATE TO HIGH ANTICHOLINERGIC ACTIVITY IN OLDER ADULTS (>65 YEARS OF AGE) Low Anticholinergic Activity; Moderate/High Anticholinergic Activity -B in combo Beers Antibiotics Antiparkinsonian Cardiovascular Agents Immunosuppressants ampicillin *ALL AVAILABLE AS amantadine SYMMETREL atenolol TENORMIN azaTHIOprine IMURAN cefOXitin GENERIC benztropine mesylate COGENTIN captopril CAPOTEN cyclosporine NEORAL clindamycin bromocriptine PARLODEL chlorthalidone GENERIC ONLY hydrocortisone CORTEF gentamicin (Oint & Sol’n NIHB covered) carbidopa/levodopa SINEMET digoxin LANOXIN, TOLOXIN methylprednisolone MEDROL piperacillin entacapone COMTAN dilTIAZem CARDIZEM, TIAZAC prednisone WINPRED dipyridamole PERSANTINE, ethopropazine PARSITAN vancomycin phenelzine NARDIL AGGRENOX disopyramide RYTHMODAN Muscle Relaxants pramipexole MIRAPEX Antidepressants baclofen LIORESAL ( on intrathecal only) procyclidine KEMADRIN furosemide LASIX amitriptyline ELAVIL cyclobenzaprine FLEXERIL selegiline ELDEPRYL hydrALAZINE APRESOLINE clomiPRAMINE ANAFRANIL isosorbide ISORDIL methocarbamol ROBAXIN OTC trihexyphenidyl ARTANE desipramine NORPRAMIN metoprolol LOPRESOR orphenadrine NORFLEX OTC doxepin >6mg SINEQUAN Antipsychotics NIFEdipine ADALAT tiZANidine ZANAFLEX A imipramine TOFRANIL quiNIDine GENERIC ONLY C ARIPiprazole ABILIFY & MAINTENA -
<I>Iguana Iguana</I>
Journal of the American Association for Laboratory Animal Science Vol 58, No 6 Copyright 2019 November 2019 by the American Association for Laboratory Animal Science Pages 810–816 Use of Rodent Sedation Tests to Evaluate Midazolam and Flumazenil in Green Iguanas (Iguana iguana) Thais F Bressan, Thayanee Sobreira, and Adriano B Carregaro* This study aimed to evaluate the applicability of rodent behavioral tests to assess the effects of midazolam and flumazenil in green iguanas. Four tests commonly used to assess sedation in rodents—the open field test, forced swim test, behavioral scale, and traction test—were conducted in 10 juveniles iguanas. The animals received midazolam (2 mg/kg IM) or 0.9% NaCl (0.4 mL/kg IM), and the tests were conducted between 0 and 300 min thereafter. To verify the effects of midazolam and flumazenil, the most informative tests from the evaluation stage and the limb withdrawal latency time (LWLT) were used. All 10 iguanas were tested under 4 conditions, as follows: MS, midazolam (2 mg/kg IM), followed 30 min later by 0.9% NaCl (0.4 mL/kg IM); FS, flumazenil (0.05 mg/kg IM), followed by 0.9% NaCl (0.4 mL/kg IM) 30 min later; MF, midazolam (2 mg/ kg IM), followed by flumazenil (0.05 mg/kg IM) 30 min later; and CON, 0.9% NaCl (0.4 mL/kg IM). The behavioral scale and the forced swim test showed the best detection of the onset, peak effect, and the differences between the sedated and con- trol iguanas, with testing done between 15 and 240 min after drug administration. -
Euthanasia of Experimental Animals
EUTHANASIA OF EXPERIMENTAL ANIMALS • *• • • • • • • *•* EUROPEAN 1COMMISSIO N This document has been prepared for use within the Commission. It does not necessarily represent the Commission's official position. A great deal of additional information on the European Union is available on the Internet. It can be accessed through the Europa server (http://europa.eu.int) Cataloguing data can be found at the end of this publication Luxembourg: Office for Official Publications of the European Communities, 1997 ISBN 92-827-9694-9 © European Communities, 1997 Reproduction is authorized, except for commercial purposes, provided the source is acknowledged Printed in Belgium European Commission EUTHANASIA OF EXPERIMENTAL ANIMALS Document EUTHANASIA OF EXPERIMENTAL ANIMALS Report prepared for the European Commission by Mrs Bryony Close Dr Keith Banister Dr Vera Baumans Dr Eva-Maria Bernoth Dr Niall Bromage Dr John Bunyan Professor Dr Wolff Erhardt Professor Paul Flecknell Dr Neville Gregory Professor Dr Hansjoachim Hackbarth Professor David Morton Mr Clifford Warwick EUTHANASIA OF EXPERIMENTAL ANIMALS CONTENTS Page Preface 1 Acknowledgements 2 1. Introduction 3 1.1 Objectives of euthanasia 3 1.2 Definition of terms 3 1.3 Signs of pain and distress 4 1.4 Recognition and confirmation of death 5 1.5 Personnel and training 5 1.6 Handling and restraint 6 1.7 Equipment 6 1.8 Carcass and waste disposal 6 2. General comments on methods of euthanasia 7 2.1 Acceptable methods of euthanasia 7 2.2 Methods acceptable for unconscious animals 15 2.3 Methods that are not acceptable for euthanasia 16 3. Methods of euthanasia for each species group 21 3.1 Fish 21 3.2 Amphibians 27 3.3 Reptiles 31 3.4 Birds 35 3.5 Rodents 41 3.6 Rabbits 47 3.7 Carnivores - dogs, cats, ferrets 53 3.8 Large mammals - pigs, sheep, goats, cattle, horses 57 3.9 Non-human primates 61 3.10 Other animals not commonly used for experiments 62 4. -
The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis
The effects of antipsychotic treatment on metabolic function: a systematic review and network meta-analysis Toby Pillinger, Robert McCutcheon, Luke Vano, Katherine Beck, Guy Hindley, Atheeshaan Arumuham, Yuya Mizuno, Sridhar Natesan, Orestis Efthimiou, Andrea Cipriani, Oliver Howes ****PROTOCOL**** Review questions 1. What is the magnitude of metabolic dysregulation (defined as alterations in fasting glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride levels) and alterations in body weight and body mass index associated with short-term (‘acute’) antipsychotic treatment in individuals with schizophrenia? 2. Does baseline physiology (e.g. body weight) and demographics (e.g. age) of patients predict magnitude of antipsychotic-associated metabolic dysregulation? 3. Are alterations in metabolic parameters over time associated with alterations in degree of psychopathology? 1 Searches We plan to search EMBASE, PsycINFO, and MEDLINE from inception using the following terms: 1 (Acepromazine or Acetophenazine or Amisulpride or Aripiprazole or Asenapine or Benperidol or Blonanserin or Bromperidol or Butaperazine or Carpipramine or Chlorproethazine or Chlorpromazine or Chlorprothixene or Clocapramine or Clopenthixol or Clopentixol or Clothiapine or Clotiapine or Clozapine or Cyamemazine or Cyamepromazine or Dixyrazine or Droperidol or Fluanisone or Flupehenazine or Flupenthixol or Flupentixol or Fluphenazine or Fluspirilen or Fluspirilene or Haloperidol or Iloperidone -
Redalyc.Tissue Depletion of Azaperone and Its Metabolite
Revista de Toxicología ISSN: 0212-7113 [email protected] Asociación Española de Toxicología España Mestorino, N.; Marchetti, M. L.; Daniele, M.; Martínez, M. A.; Martínez-Larrañaga, M. R.; Anadón, A. Tissue depletion of azaperone and its metabolite azaperol after oral administration of azaperone in food-producing pigs Revista de Toxicología, vol. 30, núm. 2, julio-diciembre, 2013, pp. 209-214 Asociación Española de Toxicología Pamplona, España Available in: http://www.redalyc.org/articulo.oa?id=91931189013 How to cite Complete issue Scientific Information System More information about this article Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal Journal's homepage in redalyc.org Non-profit academic project, developed under the open access initiative Rev. Toxicol. (2013) 30: 209-214 Tissue depletion of azaperone and its metabolite azaperol after oral administration of azaperone in food-producing pigs Mestorino N1* , Marchetti M L1 , Daniele M1 , Martínez M A2 , Martínez-Larrañaga M R2 , Anadón A2 . 1Laboratorio de Estudios Farmacológicos y Toxicológicos (LEFyT), Facultad de Ciencias Veterinarias, Universidad Nacional de La Plata, 1900- La Plata, Buenos Aires, Argentina. 2Departamento de Toxicología y Farmacología, Facultad de Veterinaria, Universidad Complutense de Madrid, 28040-Madrid, España. Recibido 5 de noviembre de 2013 / Aceptado 20 de diciembre de 2013 Abstract: Azaperone is a butyrophenone tranquilizer for swine. establecidos por la Unión Europea (100 mg / kg en el músculo, el Food producing pigs are particularly sensitive to stress during hígado, los riñones y la piel + grasa) en ningún momento del handling and transport to the abattoir. In vivo, azaperone is partially muestreo. Como consecuencia, según los resultados obtenidos en el metabolised to azaperol, a metabolite with pharmacological activity. -
Repeated Administration of Tribromoethanol in C57BL/6Nhsd Mice
Journal of the American Association for Laboratory Animal Science Vol 52, No 2 Copyright 2013 March 2013 by the American Association for Laboratory Animal Science Pages 176–179 Repeated Administration of Tribromoethanol in C57BL/6NHsd Mice William A Hill,1,3,* Jacquelyn T Tubbs,5 Christopher L Carter,3 Jane A Czarra,3 Kimberly M Newkirk,1 Tim E Sparer,4 Barton Rohrbach,1 and Christine M Egger2 We evaluated the effect of repeated intraperitoneal administration of tribromoethanol on various parameters in C57BL/6NHsd mice. Mice (n = 68) were randomly assigned to 1 of 7 groups to receive tribromoethanol (500 mg/kg IP) on day 0 or days 0 and 8; vehicle (tert-amyl alcohol in sterile water) only on day 0 or days 0 and 8; sterile water injection on day 0 or days 0 and 8; or no treatment. A single dose of tribromoethanol failed to produce loss of pedal reflex and had no effect on median food and water consumption but altered median body weight on days 1 through 4 when compared with that in mice that received vehicle only or no treatment. Median body weight did not differ between mice that received a single dose of tribromoetha- nol and those that received an injection of water. Among mice given 2 doses of tribromoethanol, induction time, anesthetic duration, and recovery time varied widely. Repeated administration of tribromoethanol had no effect on median food and water consumption or body weight compared with those in controls. Median liver weight was significantly greater in mice that received 2 doses compared with a single dose of tribromoethanol.